Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.
Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K. Noronha V, et al. Among authors: dutt a. J Clin Oncol. 2020 Jan 10;38(2):124-136. doi: 10.1200/JCO.19.01154. Epub 2019 Aug 14. J Clin Oncol. 2020. PMID: 31411950 Clinical Trial.
Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity.
Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, Upadhyay P, Utture S, Desai S, Jambhekar N, Dutt A. Chougule A, et al. Among authors: dutt a. PLoS One. 2013 Oct 4;8(10):e76164. doi: 10.1371/journal.pone.0076164. eCollection 2013. PLoS One. 2013. PMID: 24124538 Free PMC article.
Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer.
Choughule A, Sharma R, Trivedi V, Thavamani A, Noronha V, Joshi A, Desai S, Chandrani P, Sundaram P, Utture S, Jambhekar N, Gupta S, Aich J, Prabhash K, Dutt A. Choughule A, et al. Among authors: dutt a. Br J Cancer. 2014 Nov 25;111(11):2203-4. doi: 10.1038/bjc.2014.401. Epub 2014 Aug 12. Br J Cancer. 2014. PMID: 25117816 Free PMC article. No abstract available.
Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
Chandrani P, Prabhash K, Prasad R, Sethunath V, Ranjan M, Iyer P, Aich J, Dhamne H, Iyer DN, Upadhyay P, Mohanty B, Chandna P, Kumar R, Joshi A, Noronha V, Patil V, Ramaswamy A, Karpe A, Thorat R, Chaudhari P, Ingle A, Choughule A, Dutt A. Chandrani P, et al. Among authors: dutt a. Ann Oncol. 2017 Mar 1;28(3):597-603. doi: 10.1093/annonc/mdw636. Ann Oncol. 2017. PMID: 27998968 Free PMC article.
Analysis of solid tumor mutation profiles in liquid biopsy.
Balaji SA, Shanmugam A, Chougule A, Sridharan S, Prabhash K, Arya A, Chaubey A, Hariharan A, Kolekar P, Sen M, Ravichandran A, Katragadda S, Sankaran S, Bhargava S, Kulkarni P, Rao S, Sunkavalli C, Banavali S, Joshi A, Noronha V, Dutt A, Bahadur U, Hariharan R, Veeramachaneni V, Gupta V. Balaji SA, et al. Among authors: dutt a. Cancer Med. 2018 Nov;7(11):5439-5447. doi: 10.1002/cam4.1791. Epub 2018 Sep 27. Cancer Med. 2018. PMID: 30264478 Free PMC article.
391 results